Loading...
•
Sep 30, 2023
Caribou Biosciences Q3 2023 Earnings Report
Caribou Biosciences reported financial results for Q3 2023 and provided a business update.
Key Takeaways
Caribou Biosciences reported Q3 2023 financial results, highlighting advancements in their pipeline programs, including CB-010, CB-011, and CB-012. The company's cash, cash equivalents, and marketable securities totaled $396.7 million, expected to fund operations into Q4 2025.
CB-010 ANTLER Phase 1 trial continues enrolling second-line r/r LBCL patients in dose expansion; plan to share FDA feedback by year-end 2023 and report initial dose expansion data in H1 2024.
CB-011 CaMMouflage Phase 1 trial enrollment ongoing in r/r MM patients.
CB-012 AMpLify Phase 1 trial site activation underway following recent IND clearance; expect to initiate enrollment by mid-2024 in r/r AML patients.
$396.7 million in cash, cash equivalents, and marketable securities expected to fund the current operating plan into Q4 2025.
Caribou Biosciences
Caribou Biosciences
Forward Guidance
Caribou plans to meet with the FDA to discuss a potential pivotal clinical trial in second-line LBCL patients and plans to share FDA feedback by year-end 2023. The Company also plans to report initial dose expansion data in second-line LBCL patients from the ongoing ANTLER trial in H1 2024. Caribou plans to provide updates on dose escalation as the CaMMouflage Phase 1 clinical trial in r/r MM advances. Caribou plans to initiate patient enrollment in the AMpLify Phase 1 clinical trial in r/r AML by mid-2024.
Positive Outlook
- Plan to share FDA feedback by year-end 2023.
- Report initial dose expansion data in H1 2024.
- Continue to enroll second-line LBCL patients in the dose expansion portion of the ongoing ANTLER Phase 1 clinical trial.
- Provide updates on dose escalation as the CaMMouflage Phase 1 clinical trial in r/r MM advances.
- Initiate patient enrollment in the AMpLify Phase 1 clinical trial in r/r AML by mid-2024.